Skip to content Skip to sidebar Skip to footer
Subscribe Now
PharmaShots Interview Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis
VIEWPOINTS

PharmaShots Interview: Zai Lab’s Jonathan Wang Shares Insights on KarXT (xanomeline-trospium) for the Treatment of Schizophrenia And Psychosis

In an interview with PharmaShots, Jonathan Wang, Executive Vice President and Head of Business Development at Zai Lab shares his views on the license agreement with Karuna Therapeutics for KarXT (xanomeline-trospium) to treat schizophrenia and psychosis Shots: The companies collaborate to develop, manufacture & commercialize KarXT in Greater China including mainland China, Hong Kong, Macau & Taiwan Zai Lab gets exclusive rights to develop &…
February 28, 20220Comments

Read more

Viewpoints_Senior Editor
VIEWPOINTS

PharmaShots Interview: Boston Scientific’s Ron Morton Shares Insights on the Rezūm Water Vapor Therapy

In an interview with PharmaShots, Ron Morton, Chief Medical Officer, Vice President of Medical Affairs, UroPH at Boston Scientific shares his views on Rezūm Water Vapor Therapy to reduces the size of the prostate and provides lasting symptom relief from benign prostatic hyperplasia Shots: The company reported the new data from a survey of 2,000 American men aged ≥60 conducted by…
February 24, 20220Comments

Read more

Viewpoints_Tania Small
VIEWPOINTS

PharmaShots Interview: GSK’s Tania Small Shares Insight on Target the Future Program

In an interview with PharmaShots, Tania Small, Vice President of Global Medical Oncology at GSK shares her views on the launch of Target the Future Program to help address the challenges affecting the multiple myeloma community Shots: The company has launched Target the Future program to educate people in the field of multiple myeloma and address unmet needs in the community A grant of…
February 23, 20220Comments

Read more

PharmaShots Interview Novartis’ Todd Fox Shares Insight on the US FDA's Approval of Cosentyx for Enthesitis-Related Arthritis and Psoriatic Arthritis
VIEWPOINTS

PharmaShots Interview: Novartis’ Todd Fox Shares Insight on the US FDA’s Approval of Cosentyx for Enthesitis-Related Arthritis and Psoriatic Arthritis

In an interview with PharmaShots, Todd Fox, Global Medical Franchise Head, Immunology Hepatology and Dermatology at Novartis shares his views on Cosentyx in P-III (JUNIPERA) study for the treatment of enthesitis-related arthritis and psoriatic arthritis Shots: The approval is based on the P-III (JUNIPERA) study to evaluate Cosentyx (75/150mg) vs PBO in 86 children & adolescents aged 2 to 18yrs. with ERA…
February 22, 20220Comments

Read more

Exclusive_Nikhil Lalwani_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: Nikhil Lalwani of ANI Pharmaceuticals Shares Insight on Purified Cortrophin Gel

In an interview with PharmaShots, Nikhil Lalwani, President, and CEO at ANI Pharmaceuticals shared his views on the launch of Purified Cortrophin Gel for the treatment of multiple chronic autoimmune disorders Shots: The company launches Purified Cortrophin Gel for the treatment of chronic autoimmune disorders, including acute exacerbations of MS, RA, and excess urinary protein due to nephrotic syndrome Cortrophin Gel is an…
February 21, 20220Comments

Read more

PharmaShots Interview PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100
VIEWPOINTS

PharmaShots Interview: PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100

In an interview with PharmaShots, Dikla Czaczkes Akselbrad, Executive Vice President, Chief Financial Officer at PolyPid shares her views on Q3’21 financial results & P-III (SHIELD I) trial of D-PLEX100 in patients with incisional SSIs in post-abdominal surgery Shots: The P-III (SHIELD I) trial evaluates the efficacy and safety of D-PLEX100 in ~500 patients with incisional SSIs in post-abdominal surgery. The trial continues to enroll…
February 16, 20220Comments

Read more

VIEWPOINTS

PharmaShots Interview: 180 Life Sciences’ Dr. Jim Woody Shares Insight on Repurposing Anti-TNF to Meet Unmet Needs in Pain and Inflammation

In an interview with PharmaShots, Dr. Jim Woody, MD, Ph.D., Chief Executive Officer at 180 Life Sciences shared his insights on the Phase 2b study of anti-TNF for the treatment of the early Dupuytren's disease. Shots: 180 Life Sciences used anti-TNF to treat early Dupuytren’s disease and the Phase 2b study is complete. Additional programs using anti-TNF soon to…
February 15, 20220Comments

Read more

Exclusive_John Meduri_2022
EXCLUSIVE

Exclusive Interview with PharmaShots: John Meduri of Accelerate Diagnostics Shares Insight on Antimicrobial Resistance or AMR

In an interview with PharmaShots, John Meduri, Chief Strategy Officer at Accelerate Diagnostics shared his views on antimicrobial resistance and discuss the epidemiology of AMR cases in the US and worldwide. He also shared his views on Accelerate Pheno system and PhenoTest BC kit. Shots: Antibiotic resistance occurs when bacteria develop the ability to defeat…
February 14, 20220Comments

Read more

Life Sciences Deals Top 20 2021
TOP 20

Top 20 Life Sciences Deals of 2021 by Total Deal Value

Shots: The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020. Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech for a total value of $12.7B, followed by Poseida Therapeutics’ development and commercialization deal with Takeda for $3.73B. This article is based on the 2021…
February 10, 20220Comments

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]